Kiziltepe Ugursay, Eyileten Zeynep Bastuzel, Sirlak Mustafa, Tasoz Refik, Aral Atilla, Eren Neyyir Tuncay, Uysalel Adnan, Akalin Hakki
Department of Cardiovascular Surgery, Ankara University School of Medicine, Ankara, Turkey.
Int J Cardiol. 2003 Jun;89(2-3):153-8. doi: 10.1016/s0167-5273(02)00449-7.
Arrhythmias following cardiac surgery is still a difficult complication to treat. Magnesium sulfate is an effective antiarrhythmic agent with negligible side effects. In this study, effects of magnesium sulfate as a first line antiarrhythmic agent was compared with results of two different well-accepted antiarrhythmic agents.
One hundred patients with arrhythmia were prospectively randomized to a study and a control group. Lidocaine and amiodarone were accepted as standard antiarrhythmic agents. Patients in study group were received magnesium sulfate routinely as a first line antiarrhythmic agent. Unresponsive arrhythmias were treated with standard antiarrhythmic agents. Control group patients received only standard antiarrhythmics.
Magnesium sulfate alone was effective in 56% of the study group whereas 74% of the control group were responsive to standard antiarrhythmics (P=n.s.). In study group, a subgroup analysis according to blood levels of Mg2+ revealed that magnesium sulfate was more effective in patients with low Mg2+ levels (63% for low Mg2+ levels, 55% for normal Mg2+ levels, 36% for high Mg2+ levels) and ventricular arrhythmias (60% for ventricular and 40% for supraventricular arrhythmias), without statistical significance.
Magnesium sulfate is an effective and safe antiarrhythmic agent for arrhythmias developed after open-heart surgery. Its antiarrhythmic effect may relate to its pharmacological properties and unrelated to normalization of the circulating magnesium concentrations. We recommend its use as a first line antiarrhythmic agent without routine measurement of blood levels.
心脏手术后的心律失常仍然是一种难以治疗的并发症。硫酸镁是一种有效的抗心律失常药物,副作用可忽略不计。在本研究中,将硫酸镁作为一线抗心律失常药物的效果与两种不同的、被广泛认可的抗心律失常药物的效果进行了比较。
100例心律失常患者被前瞻性随机分为研究组和对照组。利多卡因和胺碘酮被视为标准抗心律失常药物。研究组患者常规接受硫酸镁作为一线抗心律失常药物。对无反应的心律失常采用标准抗心律失常药物治疗。对照组患者仅接受标准抗心律失常药物治疗。
研究组中仅硫酸镁治疗有效的患者占56%,而对照组中74%的患者对标准抗心律失常药物有反应(P值无统计学意义)。在研究组中,根据Mg2+血药浓度进行的亚组分析显示,硫酸镁在低Mg2+水平患者(低Mg2+水平者为63%,正常Mg2+水平者为55%,高Mg2+水平者为36%)和室性心律失常患者(室性心律失常者为60%,室上性心律失常者为40%)中更有效,但无统计学意义。
硫酸镁是心脏直视手术后发生的心律失常的一种有效且安全的抗心律失常药物。其抗心律失常作用可能与其药理特性有关,而与循环镁浓度的正常化无关。我们建议将其用作一线抗心律失常药物,无需常规检测血药浓度。